Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration
Summary
The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.
What changed
The USPTO published a new patent application (US20260097092A1) disclosing a pharmaceutical composition containing mitochondria-targeting compounds for treating macular degeneration and retinal diseases. The application claims compounds that specifically induce apoptosis of senescent cells, enabling prevention and treatment of aging-related ocular conditions. Inventors include Ja Hyoung Ryu, Sang Pil Kim, Do Hyun Kim, Hye Won Chung, and Jae Byoung Chae.
Pharmaceutical companies and biotech firms developing ophthalmic therapeutics or senescence-targeting therapies should review the application's claims and filing date to assess potential freedom-to-operate implications or licensing opportunities. Drug manufacturers with similar R&D programs may need to evaluate whether their compounds fall within the scope of these claims.
What to do next
- Monitor for patent grant status updates
- Review application claims for R&D alignment
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA-TARGETING COMPOUND AS ACTIVE INGREDIENT FOR TREATING MACULAR DEGENERATION
Application US20260097092A1 Kind: A1 Apr 09, 2026
Assignee
ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors
Ja Hyoung RYU, Sang Pil KIM, Do Hyun KIM, Hye Won CHUNG, Jae Byoung CHAE
Abstract
The present disclosure relates to a pharmaceutical composition for treating retinal diseases, including a mitochondria-targeting compound as an active ingredient, wherein according to one aspect, the compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same may specifically induce apoptosis of senescent cells, and thus be usefully applied for the effective prevention or treatment of aging-related diseases.
CPC Classifications
A61K 38/08 A61P 27/02
Filing Date
2023-01-11
Application No.
19113607
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from UNIST.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.